Torrent Pharmaceuticals' Q4 FY 2025-26 Quarterly Results

Result Summary

• Torrent Pharmaceuticals Ltd reported a 27.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 42.1%.
• Its expenses for the quarter were up by 45.4% QoQ and 59.2% YoY.
• The net profit decreased 42.7% QoQ and decreased 26.9% YoY.
• The earnings per share (EPS) of Torrent Pharmaceuticals Ltd stood at 11.51 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Torrent Pharmaceuticals Ltd, part of the Torrent Group, is an Indian pharmaceutical company based in Ahmedabad. It operates primarily in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of a wide range of generic and specialty medicines. The company has a strong presence in the cardiovascular, central nervous system, gastrointestinal, and women’s healthcare segments, among others. Torrent Pharmaceuticals has been known for its robust research and development capabilities, leveraging its extensive network of manufacturing and research facilities. As of the data available, there are no specific recent developments or major changes in the company’s structure or operations noted.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), Torrent Pharmaceuticals Ltd reported a total income of ₹4180.00 crores. This marks a substantial increase of 27.1% quarter-over-quarter (QoQ) compared to ₹3290.00 crores in the third quarter of fiscal year 2026 (Q3FY26). Year-over-year (YoY) growth was even more pronounced, with total income rising by 42.1% from ₹2941.00 crores in the fourth quarter of fiscal year 2025 (Q4FY25). This significant growth in revenue reflects the company's ability to enhance its market share and improve sales performance over the past year.

Profitability

Torrent Pharmaceuticals' profitability in Q4FY26 demonstrated a decline compared to the previous quarters. The profit before tax for Q4FY26 was ₹529.00 crores, which represents a decrease of 35.0% QoQ from ₹814.00 crores in Q3FY26 and a 20.5% YoY decline from ₹665.00 crores in Q4FY25. The tax expense for Q4FY26 was ₹165.00 crores, slightly down by 7.8% QoQ and marginally by 1.2% YoY. Consequently, the profit after tax for Q4FY26 stood at ₹364.00 crores, a significant reduction of 42.7% QoQ and 26.9% YoY. Earnings per share (EPS) also reflected this trend, decreasing to ₹11.51 from ₹18.77 in Q3FY26 and ₹14.71 in Q4FY25, indicating a 38.7% QoQ and 21.8% YoY decline.

Operating Metrics

The total expenses for Torrent Pharmaceuticals in Q4FY26 were ₹3585.00 crores, an increase of 45.4% QoQ from ₹2466.00 crores in Q3FY26 and 59.2% YoY from ₹2252.00 crores in Q4FY25. The surge in expenses significantly impacted the company's profitability metrics despite the strong revenue growth. The company’s operating efficiency and cost management strategies are critical factors influencing these figures. No specific information regarding the company’s debt levels or liquidity ratios, such as the P/E ratio, debt-to-equity ratio, or current ratio, is available from the provided data.